Skip to Content

Alseres Pharmaceuticals Inc ALSE

Morningstar Rating
$0.01 0.01 (50.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ALSE is trading at a 5% premium.
Price
$0.01
Fair Value
$8.40
Uncertainty
Extreme
1-Star Price
$2.45
5-Star Price
$7.49
Economic Moat
Tbzfqcw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALSE is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.01
Day Range
$0.010.01
52-Week Range
$0.010.01
Bid/Ask
$0.00 / $175.00
Market Cap
$30.64
Volume/Avg
142 / 142

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company’s lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
3

Valuation

Metric
ALSE
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ALSE
Quick Ratio
0.10
Current Ratio
0.12
Interest Coverage
−2.27
Quick Ratio
ALSE

Profitability

Metric
ALSE
Return on Assets (Normalized)
−354.18%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
ALSE
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWlwx$550.4 Bil
VRTX
Vertex Pharmaceuticals IncFrngztv$111.8 Bil
REGN
Regeneron Pharmaceuticals IncHzplgf$107.9 Bil
MRNA
Moderna IncSfg$36.3 Bil
ARGX
argenx SE ADRQmlt$23.0 Bil
BNTX
BioNTech SE ADRShbd$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncGmjkmhc$19.2 Bil
BMRN
Biomarin Pharmaceutical IncVcqzxh$16.4 Bil
RPRX
Royalty Pharma PLC Class AKmwdfsh$13.4 Bil
INCY
Incyte CorpTzdzbdw$13.3 Bil

Sponsor Center